Pulmobiotics is a spin-off company from the Centre for Genomic Regulation (CRG). Is a pre-clinical life sciences company using synthetic biology to develop a novel live biotherapeutic platform for treating human lung diseases. The platform is based on attenuated lung bacteria able to deliver therapeutic agents in the lung with different activities, i.e. antimicrobial, tissue regeneration, immune system modulation.
- CEO: Claudio Santos
- CSO & co-Founder: Dr. Maria Lluch
- Advisor & co-Founder: Prof. Luis Serrano
- Location: Barcelona
- Website: pulmobio.com